The Effects of Eprosartan Mesylate and Lercanidipine on Reducing Microalbuminuria in Patients with Nephropathy due to Type 2 Diabetes

Botir T. Daminov, PhD, ScD, Sherzod S. Abdullaev*

Tashkent Medical Academy, Tashkent, Uzbekistan

* Corresponding author:  Sherzod S. Abdullaev. Tashkent Medical Academy. Tashkent, Uzbekistan. E-mail:

Published: June 25, 2013


In total, 57 patients (31 males and 26 females) with diabetic nephropathy were studied on a comparative basis to observe the renoprotective effectiveness of eprosartan mesylate and lercanidipine.  Eprosartan mesylate revealed a higher nephroprotective effect compared with lercanidipine at comparable antihypertensive effects of equivalent doses of both these preparations.

diabetic nephropathy; eprosartan mesylate; lercanidipine.
  1. Mauer M, Fioretto P, Woredekal Y. Diabetic nephropathy. In: Schrier RW, ed. Disease of the kidney and urinary tract. Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 2083-2127.
  2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12): 851-60.
  3. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32 (Suppl 1):S13-61.
  4. Grupo Español de Estudio de la Nefropatía Diabética. Documento de Consenso 2002 sobre pautas de detección, prevención y tratamiento de la Neuropatía Diabética en España. Nefrologia 2002; 22(6):521-30. [Article in Spanish].
  5. Gaude P, Vedel P, Larssen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383-93.
  6. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1999; 86(4):1352-7.
  7. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, et al;  American Diabetes Association . Nephropathy in diabetes. Diabetes Care 2004; 27 (Suppl 1):S79-83.
  8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al;  RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861-9.
  9. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12):851-60.
  10. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163(13):1555-65.
  11. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6):1011-53.
  12. Hovind P, Tarnow L, Parving HH. Remission and regression of diabetic nephropathy. Curr Hypertens Rep 2004; 6(5): 377-382.
  13. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69(11):2057-63.
  14. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1):S1-290.
  15. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type–2 diabetes mellitus: what guidance from recent controlled randomized trials?  J Hypertens 2002; 20(11):2099-110.
  16. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45(2):281-7.
  17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130(6):461-70. 
  19. Butkevich A, Phillips RA, Sheinart KF, Tuhrim S. The effects of various definitions of dipping and daytime and nighttime on the characterization of 24h profiles of blood pressure. Blood Press Monit 2000; 5(1):19-22.
  20. Carey R. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005; 45(5):840-4.
  21. Doublier S, Salvidio G, Lupia E, Routsalainen V, Verzola D, Deferrari G, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52(4):1023-30.
  22. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48(6):1050-7.
  23. Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005; 67(5):1913-24.

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2013; 3(2):70-73. © 2013 International Medical Research and Development Corporation. All rights reserved.